{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:42:44Z","timestamp":1791492164622,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2511001"],"award-info":[{"award-number":["2024YFC2511001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["82120108007"],"award-info":[{"award-number":["82120108007"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300796"],"award-info":[{"award-number":["82300796"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370711"],"award-info":[{"award-number":["82370711"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ekir.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:36:02Z","timestamp":1749670562000},"page":"3023-3031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective Pilot Study of Plasma Cell\u2013Targeted Therapy With Bortezomib in Refractory IgA Nephropathy"],"prefix":"10.1016","volume":"10","author":[{"given":"Li","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.06.006_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J Health Econ Outcomes Res"},{"key":"10.1016\/j.ekir.2025.06.006_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1681\/ASN.2018121255","article-title":"Mortality risk in IgA nephropathy","volume":"30","author":"Glassock","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.ekir.2025.06.006_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-024-02036-1","article-title":"Drugs in development to treat IgA nephropathy","volume":"84","author":"Del","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2025.06.006_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2025.06.006_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.006_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib10","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.06.006_bib11","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2025.06.006_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.006_bib13","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ekir.2025.06.006_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.006_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.006_bib16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo","year":"2018","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"10.1016\/j.ekir.2025.06.006_bib17","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.06.006_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41581-019-0148-1","article-title":"The ubiquitin-proteasome system in kidney physiology and disease","volume":"15","author":"Meyer-Schwesinger","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib20","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1734-1140(13)71494-4","article-title":"Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts","volume":"65","author":"Zhu","year":"2013","journal-title":"Pharmacol Rep PR"},{"key":"10.1016\/j.ekir.2025.06.006_bib21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2008.579","article-title":"Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy","volume":"75","author":"Coppo","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.006_bib22","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/ndt\/gfm351","article-title":"IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence","volume":"22","author":"Forslund","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.06.006_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.ekir.2025.06.006_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/rheumatology\/ket284","article-title":"Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus","volume":"53","author":"Quartuccio","year":"2014","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.ekir.2025.06.006_bib25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.kint.2021.04.011","article-title":"Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy","volume":"100","author":"Salhi","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.006_bib26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2025.06.006_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2020030349","article-title":"Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy","volume":"32","author":"Canney","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.ekir.2025.06.006_bib29","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1681\/ASN.2019080799","article-title":"Genome-Wide Meta-analysis identifies three novel susceptibility loci and reveals ethnic heterogeneity of genetic susceptibility for IgA nephropathy","volume":"31","author":"Li","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib30","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.kint.2022.08.020","article-title":"Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy","volume":"102","author":"Luo","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.06.006_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/ijms21010189","article-title":"A new vision of IgA nephropathy: the missing link","volume":"21","author":"Sallustio","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2025.06.006_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00467-017-3652-1","article-title":"The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition","volume":"33","author":"Coppo","year":"2018","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"10.1016\/j.ekir.2025.06.006_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1159\/000519812","article-title":"The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics","volume":"52","author":"Wong","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.06.006_bib34","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/jcm11102810","article-title":"New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies","volume":"11","author":"Maixnerova","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2025.06.006_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.04.001","article-title":"IL-6 and its role in IgA nephropathy development","volume":"66","author":"Groza","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ekir.2025.06.006_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925003614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925003614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:48:48Z","timestamp":1778892528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925003614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2468024925003614"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.06.006","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Pilot Study of Plasma Cell\u2013Targeted Therapy With Bortezomib in Refractory IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}